Trust Investment Advisors trimmed its stake in shares of Eli Lilly And Co (NYSE:LLY) by 4.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,460 shares of the company’s stock after selling 1,300 shares during the quarter. Eli Lilly And Co makes up about 2.3% of Trust Investment Advisors’ portfolio, making the stock its 4th largest holding. Trust Investment Advisors’ holdings in Eli Lilly And Co were worth $1,970,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds also recently added to or reduced their stakes in the company. Avestar Capital LLC acquired a new position in Eli Lilly And Co in the 4th quarter valued at approximately $100,000. Stelac Advisory Services LLC acquired a new position in Eli Lilly And Co in the 1st quarter valued at approximately $134,000. Silvant Capital Management LLC acquired a new position in Eli Lilly And Co in the 1st quarter valued at approximately $150,000. McKinley Carter Wealth Services Inc. acquired a new position in Eli Lilly And Co in the 1st quarter valued at approximately $153,000. Finally, Truewealth LLC acquired a new position in Eli Lilly And Co in the 4th quarter valued at approximately $186,000. Institutional investors and hedge funds own 76.01% of the company’s stock.
Several equities analysts have issued reports on the stock. BMO Capital Markets upgraded shares of Eli Lilly And Co from an “underperform” rating to a “market perform” rating and upped their price target for the company from $74.00 to $79.00 in a research report on Friday, April 13th. They noted that the move was a valuation call. HC Wainwright restated a “buy” rating on shares of Eli Lilly And Co in a research report on Wednesday, April 18th. Barclays set a $98.00 price target on shares of Eli Lilly And Co and gave the company a “buy” rating in a research report on Tuesday, May 22nd. JPMorgan Chase & Co. set a $105.00 price target on shares of Eli Lilly And Co and gave the company a “buy” rating in a research report on Monday, February 26th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $91.00 price target on shares of Eli Lilly And Co in a research report on Friday, March 23rd. One research analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $93.89.
In related news, SVP Jeffrey N. Simmons sold 9,027 shares of the stock in a transaction on Thursday, May 3rd. The shares were sold at an average price of $78.50, for a total transaction of $708,619.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Susan Mahony sold 5,165 shares of the stock in a transaction on Friday, April 13th. The stock was sold at an average price of $80.14, for a total transaction of $413,923.10. Following the transaction, the senior vice president now directly owns 45,652 shares in the company, valued at $3,658,551.28. The disclosure for this sale can be found here. Over the last three months, insiders have sold 987,464 shares of company stock worth $82,748,955. 0.11% of the stock is owned by insiders.
Shares of NYSE:LLY traded up $0.15 during trading on Wednesday, reaching $86.97. The stock had a trading volume of 52,949 shares, compared to its average volume of 3,429,815. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.01 and a current ratio of 1.41. Eli Lilly And Co has a 52 week low of $73.69 and a 52 week high of $89.09. The firm has a market cap of $93.47 billion, a P/E ratio of 20.29, a P/E/G ratio of 1.46 and a beta of 0.29.
Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Tuesday, April 24th. The company reported $1.34 EPS for the quarter, beating the Zacks’ consensus estimate of $1.13 by $0.21. Eli Lilly And Co had a net margin of 4.82% and a return on equity of 35.37%. The company had revenue of $5.70 billion for the quarter, compared to analyst estimates of $5.51 billion. During the same period in the prior year, the firm posted $0.98 EPS. The company’s quarterly revenue was up 9.0% on a year-over-year basis. sell-side analysts anticipate that Eli Lilly And Co will post 5.15 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Monday, September 10th. Investors of record on Wednesday, August 15th will be paid a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a yield of 2.59%. The ex-dividend date is Tuesday, August 14th. Eli Lilly And Co’s dividend payout ratio is presently 52.57%.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.